Literature DB >> 11826482

The integrated genome map of Mycobacterium leprae.

K Eiglmeier1, S Simon, T Garnier, S T Cole.   

Abstract

The integrated map of the Mycobacterium leprae genome unveiled for the first time the genomic organization of this obligate intracellular parasite. Selected cosmid clones, isolated from a genomic library created in the cosmid vector Lorist6, were identified as representing nearly the complete genome and were subsequently used in the M. leprae genome sequencing project. Now a new version of the integrated map of M. leprae can be presented, combining the mapping results from the Lorist6 cosmids with data obtained from a second genomic library constructed in an Escherichia coli-mycobacterium shuttle cosmid, pYUB18. More than 98% of the M. leprae genome is now covered by overlapping large insert genomic clones representing a renewable source of well defined DNA segments and a powerful tool for functional genomics.

Entities:  

Mesh:

Year:  2001        PMID: 11826482

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  4 in total

Review 1.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

2.  Rv1106c from Mycobacterium tuberculosis is a 3beta-hydroxysteroid dehydrogenase.

Authors:  Xinxin Yang; Eugenie Dubnau; Issar Smith; Nicole S Sampson
Journal:  Biochemistry       Date:  2007-07-14       Impact factor: 3.162

Review 3.  Current approaches and future directions in the treatment of leprosy.

Authors:  Sophie M Worobec
Journal:  Res Rep Trop Med       Date:  2012-08-01

4.  High accuracy mass spectrometry analysis as a tool to verify and improve gene annotation using Mycobacterium tuberculosis as an example.

Authors:  Gustavo A de Souza; Hiwa Målen; Tina Søfteland; Gisle Saelensminde; Swati Prasad; Inge Jonassen; Harald G Wiker
Journal:  BMC Genomics       Date:  2008-07-02       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.